ArticleJournal of clinical laboratory analysis2022
MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Cadmium exposure induces renal fibrosis by inhibiting hsa_circ_0075684/miR-363-3p/KLF4 signaling pathway.Scientific reports · 2026Article
- Potential role of DKK3 and WIF1 in prostate cancer: bioinformatics and clinical analysis.Discover oncology · 2025Article
- Inducer microRNAs in the glioma development: a concise review of mechanisms and insights into targeted therapy.Journal of the Egyptian National Cancer Institute · 2025Review
- GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway.Biochemical genetics · 2025Article
- ADAMDEC1 promotes cervical squamous cell carcinoma by enhancing the JAK/STAT signaling pathway through modulation of TYMP.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- ARNTL2: a key player in promoting tumor aggressiveness in papillary thyroid cancer.Translational cancer research · 2025Article
- Diagnostic Value of Glycosylated Extracellular Vesicle microRNAs in Gastric Cancer.Cancer management and research · 2025Article
- Research advances on the risk of prostate cancer from phthalates exposure: from epidemiological evidence to multidimensional prevention and control.Frontiers in cell and developmental biology · 2025Review
- MiR-363-3p induces tamoxifen resistance in breast cancer cells through PTEN modulation.Scientific reports · 2024Article
- Comprehensive cataloging of miR-363 as a therapeutic & non-invasive biomarker of prostate cancer.The Indian journal of medical research · 2024Article
- Role of microRNA-363 during tumor progression and invasion.Journal of physiology and biochemistry · 2024Review
- P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway.Medical oncology (Northwood, London, England) · 2024Article
- MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2.Functional & integrative genomics · 2023Article
- MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is a frequent malignant tumor worldwide with high morbidity along with mortality. MicroRNAs (miRNAs) have been identified as key posttranscriptional modulators in diverse cancers. Herein, we purposed to explore the impacts of miR-363-3p on PCa growth, migration, infiltration along with apoptosis.
methodsThe expressions of miR-363-3p along with Dickkopf 3 (DKK3) were assessed in clinical PCa specimens. We adopted the PCa cell line PC3 and transfected it using miR-363-3p repressors or mimic. The relationship of miR-363-3p with DKK3 was verified by a luciferase enzyme reporter assay. Cell viability along with apoptosis were determined by MTT assay coupled with flow cytometry analysis. Cell migration along infiltration were detected via wound healing, as well as Transwell assays. The contents of DKK3, E-cadherin, vimentin along with N-cadherin were analyzed via Western blotting accompanied with qRT-PCR.
resultsMiR-363-3p was found to be inversely associated with the content of DKK3 in clinical PCa specimens. Further investigations revealed that DKK3 was miR-363-3p's direct target. Besides, overexpression of miR-363-3p decreased the contents of DKK3, promoted cell viability, migration coupled with infiltration, and reduced cell apoptosis, while silencing of miR-363-3p resulted in opposite influence. Upregulation of miR-363-3p diminished E-cadherin contents but increased vimentin along with N-cadherin protein contents in PC3 cells; in contrast, miR-363-3p downregulation produced the opposite result.
conclusionOur study indicates that miR-363-3p promotes PCa growth, migration coupled with invasion while dampening apoptosis by targeting DKK3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.